

Rain Therapeutics to Present at Upcoming Virtual Investor Conferences

B. Riley Securities virtual presentation scheduled for January 27th at 3:30 pm ET

Guggenheim Oncology virtual fireside chat scheduled for February 10th at 4:00 pm ET

NEWARK, Calif., Tuesday, January 25, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the B. Riley Securities Oncology Investor Conference on Thursday, January 27th at 3:30 pm ET, and Rain will be highlighted in a virtual fireside chat at the Guggenheim Oncology Conference with research analyst Michael Schmidt on Thursday, February 10th at 4:00 pm ET. The fireside chat will feature an interactive discussion with Rain's co-founder, chairman and CEO, Avanish Vellanki.

Additional details can be found below:

Conference: B. Riley Securities Oncology Investor Conference

Date and Time: Thursday, January 27th, 2022 at 3:30-4:00 pm ET.

Registration: Webcast link [here](#).

Conference: Guggenheim Oncology Conference

Date and Time: Thursday, February 10th, 2022 at 4:00-4:25 pm ET.

Registration: Webcast link [here](#).

Replays of the corporate overview presentation and fireside chat will be available by visiting the "[Events](#)" section of the Rain website after the conclusion of the events and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact

Jordyn Temperato

LifeSci Communications

jtemperato@lifescicomms.com

Investor Contact

Bob Yedid

LifeSci Advisors

+1.646.597.6989

bob@lifesciadvisors.com